Table 2.
Univariable and multivariable analyses of prognostic factors for TTF and OS in melanoma patients treated with first-line nivolumab or pembrolizumab. Gender, age, TILs, BMI, NLR, LDH, sPD-L1, sPD-1, sBTN3A1, and sBTN2A1 were evaluated in the Cox regression model.
TTF | Univariable Cox regression | Multivariable Cox regression | ||
---|---|---|---|---|
HR (95% CI) | p Value | HR (95% CI) | p Value | |
Gender (M versus F) |
0.75 (0.34–1.65) | NS | ||
Age (⩽45 versus >45 years) |
0.46 (0.21–1.00) | 0.04 | 1.13 (0.45–2.82) | NS |
TILs (Absent/non-brisk versus present brisk) |
0.25 (0.07–0.91) | 0.03 | 0.25 (0.6–1.07) | NS |
BMI (<25 versus ⩾25) |
0.46 (0.21–1.02) | 0.04 | 0.37 (1.15–0.89) | 0.02 |
NLR (⩽2.6 versus >2.6) |
2.26 (1.00–5.11) | 0.04 | 1.63 (0.60–4.36) | NS |
LDH (⩽300 versus >300) |
2.11 (0.96–4.63) | 0.05 | ||
sPD-L1 (<1.17 versus ⩾1.17) |
1.25 (0.54–2.89) | NS | ||
sPD-1 (<11.24 versus ⩾11.24) |
3.62 (1.51–8.67) | 0.002 | 4.5 (1.71–12.03) | 0.002 |
sBTN3A1 (<9.7 versus ⩾ 9.7) |
0.89 (0.34–2.00) | NS | ||
sBTN2A1 (<4.0 versus ⩾4.0) |
0.44 (0.19–0.97) | 0.03 | 0.57 (0.23–1.37) | NS |
OS | Univariable Cox regression | Multivariable Cox regression | ||
HR (95% CI) | P Value | HR (95% CI) | p Value | |
Gender (M versus F) |
0.74 (0.32–1.70) | NS | ||
Age (⩽45 versus >45 years) |
0.94 (0.41–2.12) | NS | ||
TILs (Absent/non-brisk versus present brisk) |
0.35 (0.10–1.25) | NS | ||
BMI (<25 versus ⩾25) |
0.52 (0.23–1.18) | NS | ||
NLR (⩽2.6 versus >2.6) |
2.15 (0.94–4.93) | 0.06 | ||
LDH (⩽300 versus >300) |
2.54 (1.07–6.05) | 0.02 | 1.79 (0.67–4.78) | NS |
sPD-L1 (<1.17 versus ⩾1.17) |
1.31 (0.55–3.09) | NS | ||
sPD-1 (<11.24 versus ⩾11.24) |
2.44 (1.05–5.68) | 0.03 | 1.79 (0.67–4.78) | NS |
sBTN3A1 (<9.7 versus ⩾9.7) |
0.85 (0.37–1.95) | NS | ||
sBTN2A1 (<4.0 versus ⩾4.0) |
0.85 (0.38–1.91) | NS |
BMI, body mass index; CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; sBTN, soluble butyrophilin; sPD-1, soluble programmed cell death protein 1; sPD-L1, soluble programmed cell death ligand 1; TILs, tumor-infiltrating lymphocytes; TTF, time to treatment failure.